Page 131 - 南京医科大学学报自然科学版
P. 131

第43卷第11期              王盛锦,王 峰,孙 锋. 循环肿瘤DNA检测在胃肠间质瘤诊疗中的价值[J].
                 2023年11月                    南京医科大学学报(自然科学版),2023,43(11):1596-1604                      ·1603 ·


                    trointestinal stromal tumor[J]. Mol Diagn Ther,2016,20  lized medicine[J]. Annu Rev Pathol Mech Dis,2022,17:
                    (4):347-351                                        323-344
               [30]DALLE F C,GUARDASCIONE M,DE MATTIA E,et al.   [42] JANKU F,ABDUL RAZAK A R,CHI P,et al. Switch con⁃
                    Clonal selection of a novel deleterious TP53 somatic muta⁃  trol inhibition of KIT and PDGFRA in patients with ad⁃
                    tion discovered in ctDNA of a KIT/PDGFRA wild ⁃ type  vanced gastrointestinal stromal tumor:a phase I study of
                    gastrointestinal stromal tumor resistant to imatinib[J].  ripretinib[J]. J Clin Oncol,2020,38(28):3294-3303
                    Front Pharmacol,2020,11:36                   [43] BLAY J Y ,SERRANO C,HEINRICH M C,et al.
               [31] 中华医学会外科学分会胃肠外科学组,中国医师协会                            Ripretinib in patients with advanced gastrointestinal stro⁃
                    外科医师分会胃肠道间质病诊疗专业委员会,中国临                            mal tumours(INVICTUS):a double⁃blind,randomised,
                    床肿瘤学会胃肠间质瘤专家委员会,等. 胃肠间质瘤全                          placebo⁃controlled,phase 3 trial[J]. Lancet Oncol,2020,
                    程化管理中国专家共识(2020版)[J]. 中国实用外科杂                      21(7):923-934
                    志,2020,40(10):1109-1119                      [44] GEORGE S,VON MEHREN M,FLETCHER J,et al.
               [32] 石维坤,张信华,何裕隆. 酪氨酸激酶抑制剂与手术在                          Phase Ⅱ study of ponatinib in advanced gastrointestinal
                    进展期胃肠间质瘤中的作用[J]. 消化肿瘤杂志(电子                         stromal tumors:efficacy,safety,and impact of liquid biopsy

                    版),2019,11(1)10-15                                 and other biomarkers[J]. Clin Cancer Res,2022,28(7):
               [33] SHARMA A K,DE LA TORRE J,IJZERMAN N S,et al.       1268-1276
                    Location of gastrointestinal stromal tumor(GIST)in the  [45] KANG G,BAE B N,SOHN B S,et al. Detection of KIT
                    stomach predicts tumor mutation profile and drug sensiti⁃  and PDGFRA mutations in the plasma of patients with
                    vity[J]. Clin Cancer Res,2021,27(19):5334-5342     gastrointestinal stromal tumor[J]. Target Oncol,2015,10
               [34] JAKHETIYA A,GARG P,PRAKASH G,et al. Targeted      (4):597-601
                    therapy of gastrointestinal stromal tumours[J]. World J  [46] WADA N,KUROKAWA Y,TAKAHASHI T,et al. Detec⁃
                    Gastrointest Surg,2016,8(5):345-352                ting secondary C⁃KIT mutations in the peripheral blood of
               [35] RAITIO A,SALIM A,MULLASSERY D,et al. Current       patients with imatinib⁃resistant gastrointestinal stromal tu⁃
                    treatment and outcomes of pediatric gastrointestinal stro⁃  mor[J]. Oncology,2016,90(2):112-117
                    mal tumors(GIST):a systematic review of published stud⁃  [47] SERRANO C,LEAL A,KUANG Y N,et al. Phase I study
                    ies[J]. Pediatr Surg Int,2021,37(9):1161-1165      of rapid alternation of sunitinib and regorafenib for the
               [36] 中国药学会医院药学专业委员会,中国药理学会治疗                            treatment of tyrosine kinase inhibitor refractory gastroin⁃
                    药物监测研究专业委员会,《胃肠间质瘤靶向药物的治                           testinal stromal tumors[J]. Clin Cancer Res,2019,25
                    疗药物监测中国专家共识》编写组. 胃肠间质瘤靶向药                         (24):7287-7293
                    物的治疗药物监测中国专家共识[J]. 中国医院药学杂                   [48] NAMLØS H M,BOYE K,MISHKIN S J,et al. Noninva⁃
                    志,2021,41(20):2041-2049                            sive detection of ctDNA reveals intratumor heterogeneity
               [37] 孙祥飞,高晓东,沈坤堂. 胃肠间质瘤中伊马替尼继发                          and is associated with tumor burden in gastrointestinal
                    性耐药机制的研究进展[J]. 中华胃肠外科杂志,2019,                      stromal tumor[J]. Mol Cancer Ther,2018,17(11):2473-
                    22(9):886-790                                      2480
               [38] KALFUSOVA A ,LINKE Z,KALINOVA M,et al. Gas⁃  [49] KO T K,LEE E,NG C C Y,et al. Circulating tumor DNA
                    trointestinal stromal tumors:summary of mutational status  mutations in progressive gastrointestinal stromal tumors
                    of the primary/secondary KIT/PDGFRA mutations,BRAF  identify biomarkers of treatment resistance and uncover
                    mutations and SDH defects[J]. Pathol Res Pract,2019,  potential therapeutic strategies[J]. Front Oncol,2022,
                    215(12):152708                                     12:840843
               [39] SERRANO C,MARIÑO⁃ENRÍQUEZ A,TAO D L,et al.   [50] 赵   刚,汪    明. NCCN《软组织肉瘤临床实践指南
                    Complementary activity of tyrosine kinase inhibitors  (2018 年第 1 版)》胃肠间质瘤内容更新介绍与解读
                    against secondary kit mutations in imatinib⁃resistant gas⁃  [J]. 中国实用外科杂志,2018,38(5):515-519
                    trointestinal stromal tumours[J]. Br J Cancer,2019,120  [51] 王  健,沈朝勇,张  波. 胃肠间质瘤个体化治疗策略
                    (6):612-620                                        的探讨[J]. 中华结直肠疾病电子杂志,2019,8(3):
               [40] 吴昀紫,魏     千,马亮亮,等. 胃肠间质瘤分子发病机制                     217-220
                    及精准治疗研究进展[J]. 中国医学前沿杂志(电子                    [52] JOHANSSON G,BERNDSEN M,LINDSKOG S,et al.
                    版),2022,14(11):59-66                               Monitoring circulating tumor DNA during surgical treat⁃
               [41] DERMAWAN J K,RUBIN B P. Molecular pathogenesis     ment in patients with gastrointestinal stromal tumors[J].
                    of gastrointestinal stromal tumor:a paradigm for persona⁃  Mol Cancer Ther,2021,20(12):2568-2576
   126   127   128   129   130   131   132   133   134   135   136